So, one way or the other the stock gets to .20-.25 cents this year. Then they do an RS, then the pps weeps down to the $1-$2 range, and then things pop or not based on PRs.
There will be no huge revenue for Lympro any time soon based on current numbers. NOW, if someone wants to buy Lympro that could happen. That is a long shot, in light of the Amvid experience.
As far as long term pps that will NOT depend on PRs, but on the actual results of studies and revenue for Lympro. It takes a long time for the results of studies to come out.
If all goes well, and it MANF is advancing on a number of fronts then they will sell AMBS for $$$$.
If you asked JN, from seeking alpha how likely it is that MANF will see the clinic, I would bet that he will answer with numbers in the range he did when he first started writing about AMBS.
regarding the Lympro roll out. Well, if pharma was interested they would not need to go to Denmark. They would just show up at BD or whatever, and that would be that. Then they would not need a pre conference twitter conference to get the penny investors ready to react properly.
Things are just not done this way. That is not to say that they will not work, but well, folks around GC do have a lot of experience while this is GC's first roll out.
Market Data 
Markets 
AI
